Leber hereditary optic neuropathy
Conditions
Interventions
1. Clinical trial medicine: Idebenone 900mg/day 2. Objectives: 50 patients with LHON 3. Exclusion criteria: a) A smoker b) A patient with abnormality of hepatic function c) A patient who pre
a) At the base line: Visual acuity (VA), Critical flicker frequency (CFF), Visual field (VF: Humphry 30-2), central retinal thickness (CRT), functional MRI (f-MRI), searching the mitochondrial mutatio
Sponsors
Hyogo College of Medicine
Kitasato University Jikei University School of Medicine Tokyo Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 50 patients with LHON
Exclusion criteria
Exclusion criteria: a) A smoker b) A patient with abnormality of hepatic function c) A patient who present seizures, delirium and hallucination d) Pregnancy or Lactation e) A patient who is associated with agranulocytosis f) A patient with chronic renal failure g) A patient with anaphylactic shock against Idebenone
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Visual acuity (at 12 months after the start of the study drug) | — |
Secondary
| Measure | Time frame |
|---|---|
| Visual acuity (at 6 months after the start of the study drug), Visual field (at 6 and 12 months after the start of the study drug), Critical flicker frequency (at 6 and 12 months after the start of the study drug), central retinal thickness (at 6 and 12 months after the start of the study drug) | — |
Countries
Japan
Contacts
Public ContactHiroto Ishikawa
Hyogo College of Medicine Ophthalmology
Outcome results
None listed